large B-cell lymphoma (Cancer)
Information
- Disease name
- large B-cell lymphoma
- Disease ID
- DOID:0081452
- Description
- "A B-cell lymphoma that is characterized by large lymphoid cells of the B-cell lineage that by definition form sheets or clusters." [url:https\://pubmed.ncbi.nlm.nih.gov/37190213/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04566978 | Active, not recruiting | Early Phase 1 | 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) | September 11, 2020 | September 11, 2025 |
| NCT03642626 | Active, not recruiting | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | December 18, 2018 | June 1, 2028 | |
| NCT05108805 | Active, not recruiting | N/A | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | December 2, 2021 | December 31, 2024 |
| NCT04690192 | Active, not recruiting | Phase 1/Phase 2 | CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma | January 1, 2021 | December 30, 2024 |
| NCT05733650 | Approved for marketing | Expanded Access Program for Epcoritamab | |||
| NCT05776160 | Available | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | |||
| NCT06167785 | Not yet recruiting | Phase 2 | A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T | August 2024 | December 2027 |
| NCT06071871 | Not yet recruiting | Phase 2 | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | April 30, 2024 | July 31, 2028 |
| NCT06343311 | Not yet recruiting | Phase 1/Phase 2 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | June 15, 2024 | December 31, 2027 |
| NCT06142188 | Not yet recruiting | Relmacabtagene Autoleucel in Hematologic Malignancies | December 28, 2023 | December 31, 2038 | |
| NCT05404048 | Recruiting | Phase 2 | PD-L1 PET-imaging During CAR T-cell Therapy | May 18, 2022 | May 2025 |
| NCT05429268 | Recruiting | Phase 3 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | December 23, 2022 | December 24, 2026 |
| NCT05464719 | Recruiting | Phase 2 | A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy | September 23, 2022 | January 30, 2026 |
| NCT05472610 | Recruiting | Phase 2 | Study of Efficacy of BZ019 in Large B-cell Lymphoma | June 4, 2021 | January 2023 |
| NCT05643742 | Recruiting | Phase 1/Phase 2 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | March 10, 2023 | February 2030 |
| NCT05648019 | Recruiting | Phase 2 | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | March 15, 2022 | December 2026 |
| NCT05665062 | Recruiting | Phase 1 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | June 24, 2022 | November 2026 |
| NCT03960840 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL | June 26, 2019 | June 30, 2027 |
| NCT05757700 | Recruiting | Phase 1 | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | February 23, 2023 | February 23, 2025 |
| NCT05794958 | Recruiting | Phase 1 | Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel | May 23, 2023 | April 1, 2038 |
| NCT05820841 | Recruiting | Phase 3 | Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma | June 7, 2023 | December 2028 |
| NCT05887167 | Recruiting | Phase 1 | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | March 2, 2024 | December 15, 2026 |
| NCT05940272 | Recruiting | Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers | July 3, 2023 | July 3, 2028 | |
| NCT06045247 | Recruiting | Phase 2 | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | January 5, 2024 | July 31, 2030 |
| NCT06047080 | Recruiting | Phase 3 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | September 18, 2023 | February 28, 2029 |
| NCT06104592 | Recruiting | Phase 2 | Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL | November 8, 2023 | October 2027 |
| NCT06142175 | Recruiting | Relmacabtagene Autoleucel in Patients With LBCL | December 28, 2022 | December 31, 2024 | |
| NCT06375733 | Recruiting | Phase 1/Phase 2 | A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL | March 20, 2024 | December 31, 2026 |
| NCT04889716 | Recruiting | Phase 2 | CAR-T Followed by Bispecific Antibodies | November 5, 2021 | December 31, 2025 |
| NCT05020678 | Recruiting | Phase 1 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | August 20, 2021 | December 2038 |
| NCT05326243 | Recruiting | Phase 1/Phase 2 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | May 31, 2022 | March 31, 2026 |
| NCT05377307 | Recruiting | Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy | December 29, 2022 | December 2037 | |
| NCT06285422 | Recruiting | Phase 1 | Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) | May 2024 | March 2029 |
| NCT06356129 | Recruiting | Phase 3 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | June 24, 2024 | November 20, 2029 |
| NCT04250324 | Unknown status | Phase 1 | Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma | November 19, 2019 | December 2022 |
| NCT05929716 | Withdrawn | Phase 2 | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | September 30, 2023 | March 1, 2028 |
| NCT04503538 | Withdrawn | N/A | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | December 2020 | November 2023 |
- Disase is a (Disease Ontology)
- DOID:707